Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications

KRAS mutational subtype and copy number predict in vitro response of human pancreatic cancer cell lines to MEK inhibition

(2014) H Hamidi et al.   BRITISH JOURNAL OF CANCER

Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy

(2014) Woonyoung Choi et al.   CANCER CELL

Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma

(2014) Mitesh J. Borad et al.   PLoS Genetics

A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe

(2013) P. Bertuccio et al.   ANNALS OF ONCOLOGY

Releasing the Block: Setting Differentiation Free with Mutant IDH Inhibitors

(2013) Christopher J. Pirozzi et al.   CANCER CELL

Molecular characterization of gallbladder cancer using somatic mutation profiling

(2013) Milind Javle et al.   HUMAN PATHOLOGY

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma

(2013) Benjamin Goeppert et al.   MODERN PATHOLOGY

Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics

(2013) Rashmi Kanagal-Shamanna et al.   MODERN PATHOLOGY

Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas

(2013) Yuchen Jiao et al.   NATURE GENETICS

Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies

(2013) D Sia et al.   ONCOGENE

Obesity and cholangiocarcinoma

(2013) Mansour A Parsi   WORLD JOURNAL OF GASTROENTEROLOGY

Identification of Targetable FGFR Gene Fusions in Diverse Cancers

(2013) Yi-Mi Wu et al.   Cancer Discovery

K-ras Mutation is Strongly Associated with Perineural Invasion and Represents an Independent Prognostic Factor of Intrahepatic Cholangiocarcinoma after Hepatectomy

(2012) Tse-Ching Chen et al.   ANNALS OF SURGICAL ONCOLOGY

Cancer Epigenetics: From Mechanism to Therapy

(2012) Mark A. Dawson et al.   CELL

Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma

(2012) Benjamin R. Kipp et al.   HUMAN PATHOLOGY

Tumours associated with BAP1 mutations

(2012) Rajmohan Murali et al.   PATHOLOGY

Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

(2012) Ron Bose et al.   Cancer Discovery

Whole Cancer Genome Sequencing by Next-Generation Methods

(2011) Jeffrey S. Ross et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Risk factors for cholangiocarcinoma

(2011) Gia L. Tyson et al.   HEPATOLOGY

Rising trends in cholangiocarcinoma: Is the ICD classification system misleading us?

(2011) Shahid A. Khan et al.   JOURNAL OF HEPATOLOGY

New driver mutations in non-small-cell lung cancer

(2011) William Pao et al.   LANCET ONCOLOGY

Germline mutations in BAP1 predispose to melanocytic tumors

(2011) Thomas Wiesner et al.   NATURE GENETICS

Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping

(2011) D. R. Borger et al.   ONCOLOGIST

Descriptive Epidemiology of Cholangiocarcinoma and Clonorchiasis in Korea

(2010) Hai-Rim Shin et al.   JOURNAL OF KOREAN MEDICAL SCIENCE

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas

(2010) J. W. Harbour et al.   SCIENCE

The Expression of Phospho-AKT, Phospho-mTOR, and PTEN in Extrahepatic Cholangiocarcinoma

(2009) J.-Y. Chung et al.   CLINICAL CANCER RESEARCH

Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer

(2009) Prithviraj Bose et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing

(2009) Andreas Gnirke et al.   NATURE BIOTECHNOLOGY

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer

(2008) N Nakayama et al.   BRITISH JOURNAL OF CANCER

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE